DOCSLIB.ORG

Cannabis and Mental Health: an Environmental Scan and Scoping Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cannabis and Mental Health: an Environmental Scan and Scoping Review Cannabis and Mental Health: an Environmental Scan and Scoping Review April 26, 2019 1 This report is authored by: Fiona Clement, PhD 1,2,3 Caroline Corbett, PhD1 Brenlea Farkas, MSc 1 Mark Hofmeister, MSc1 Ruth Diaz, MSc 1 John Taplin, BA 1 Matthew Hill, PhD 4,5,6,7 Scott Patten, MD, PhD 2,3,4,5,7 Rebecca Haines-Saah, PhD 2,3,5,7 1Health technology Assessment Unit, Cumming School of Medicine, University of Calgary 2Department of Community Health Sciences, Cumming School of Medicine, University of Calgary 3O’Brien Institute of Public Health, Cumming School of Medicine, University of Calgary 4Department of Psychiatry, Cumming School of Medicine, University of Calgary 5 Mathison Centre for Mental Health Education & Research, Cumming School of Medicine, University of Calgary 6Department of Cell Biology and Anatomy, Cumming School of Medicine, University of Calgary 7Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary Cite as: Clement FM, Corbett C, Farkas B, Hofmeister M, Diaz R, Taplin J, Hill M, Patten SB, Haines-Saah RJ. Cannabis and Mental Health: An Environmental Scan and Scoping Review. Produced for the Mental Health Commission of Canada. April 2019. 2 Table of Contents Executive Summary ........................................................................................................................ 7 1. Introduction ............................................................................................................................. 9 2. Non-Medical Cannabis Legislations in Canada .................................................................... 10 3. Data Assets in Canada ........................................................................................................... 18 3.1. Trends in Cannabis Use ..................................................................................................... 23 3.1.1. Data used ..................................................................................................................... 23 3.1.2. Past-year Cannabis Use ............................................................................................... 23 3.1.3. Frequency of Cannabis Use ......................................................................................... 25 3.1.4. Age of First Time Cannabis Use ................................................................................. 28 3.1.5. Self-Reported Mental Health by Cannabis Use in Canada 2013-2017 ....................... 29 3.3 Prevalence of Mental Disorders in Canada by Cannabis use .............................................. 30 3.3.1.2. Mental Health Disorders by Cannabis Use ............................................................... 31 3.3.1.3. Prevalence of Cannabis Use Disorder Past- 12 Month ............................................. 32 4. Data assets of other legalized jurisdictions ............................................................................ 34 4.1 Models of Legalization................................................................................................... 35 4.2 Data Assets ..................................................................................................................... 38 4.3 Trends in Cannabis Use Pre- and Post-legalization ...................................................... 40 4.3.1 Data used ...................................................................................................................... 40 4.3.2 Past-Year Prevalence of Cannabis Use Pre-Post Legalization- Overall ....................... 41 4.3.3 Past-Year Prevalence of Cannabis Use Pre-Post Legalization- by Sex ........................ 42 4.3.4 Past-Year Prevalence of Cannabis Use Pre-Post Legalization- by Age C ................... 44 4.3.5 Past-Year Prevalence of Cannabis Use Pre-Post Legalization- by Age and Sex ........ 46 5. Scoping Review ..................................................................................................................... 49 5.1 Methods overview .......................................................................................................... 49 5.2 Overview of included studies ......................................................................................... 50 5.3 Preclinical Research ....................................................................................................... 54 5.3.1 Preclinical Animal Studies ........................................................................................... 54 5.3.2 Preclinical Human Studies: Brain outcomes in Humans ........................................ 57 5.4 Mental Health Outcome studies .................................................................................... 61 5.4.1 Mental Health in Community Populations ............................................................. 61 5.4.2 Clinical Population Outcomes ................................................................................ 69 5.5 Qualitative studies within this Literature ....................................................................... 76 5.6 Sex and Gender within this Literature........................................................................... 78 5.7 Indigenous Peoples within this Literature ...................................................................... 79 5.8 Knowledge strengths and gaps ....................................................................................... 81 5.8.1 Preclinical Animal Studies ...................................................................................... 81 5.8.2 Human Studies ........................................................................................................ 82 6. Moving Forward .................................................................................................................... 84 3 Appendix 1. Summary of Surveys Available for Analysis ........................................................... 87 Appendix 2. Cannabis Regulations in Other Jurisdictions ........................................................... 96 Appendix 3. Additional Pre-Post Legalization Figures .............................................................. 108 Appendix 4. Search Strategy for Scoping Review ...................................................................... 109 Appendix 5. PRISMA-ScR Checklist108 ..................................................................................... 113 Appendix 6. Inclusion/Exclusion Criteria for Scoping Review .................................................. 114 Appendix 7. References of Included Studies in Scoping Review .............................................. 116 Appendix 8: Published Literature on Indigenous Peoples .......................................................... 125 References ................................................................................................................................... 131 4 List of Figures Figure 3.1. Prevalence of Cannabis Use Past 12 Months in Canada 2013-2017 23 Figure 3.2. Prevalence of Past-Year Cannabis Use in Canada 2013-2017 by Age 24 Figure 3.2. Prevalence of Past-Year Cannabis Use in Canada 2013-2017 by Age 26 Figure 3.4. Frequency of Cannabis Use in Past Three Months among those who 27 Used Cannabis in the Past 12 Months in Canada 2013-2017 by Age Group Figure 3.5. Mean Age First Time Cannabis Use in Canada 2013 – 2017 28 Figure 3.6. Self-Reported Mental Health by Cannabis Use in Canada 2013 – 2017 29 Figure 3.7. Prevalence of Cannabis Use Disorder Past 12 Months in the Canadian 32 Household Population Figure 3.8. Prevalence of Cannabis Use Disorder Past 12 Months in Canada in 2012 32 by Age and Sex Figure 4.1. Year of non-medical cannabis legalization in US jurisdictions 34 Figure 4.2. Prevalence of past year cannabis use pre-post legalization in 7 41 jurisdictions Figure 4.3. Prevalence of past-year cannabis use pre-post legalization for males 43 Figure 4.4. Prevalence of past-year cannabis use pre-post legalization for females 43 Figure 4.5. Prevalence of past-year cannabis use pre-post legalization by age: US 44 12-17; Uruguay 13-17 years old Figure 4.6. Prevalence of past-year cannabis use pre-post legalization by age: 50 45 years or older Figure 4.7. Prevalence of past-year cannabis use pre-post legalization for males 47 under 18 years of age. US: 12-17 years old; Uruguay: 13-17 years old Figure 4.8. Prevalence of past-year cannabis use pre-post legalization for females 47 under 18 years of age. US: 12-17 years old; Uruguay: 13-17 years old Figure 4.9. Prevalence of past-year cannabis use pre-post legalization, males 18-25 48 years old Figure 4.10. Prevalence of past-year cannabis use pre-post legalization, females 18- 48 25 years old Figure 5.1. Flowchart of included studies in scoping review 51 Figure 5.2. Number of Studies in Each Research Category 52 Figure 5.3. Number of Studies per Country (research institute or study population), 53 by Research Category Figure 5.4. Number of Studies Conducted by Publication Year and Research Area 53 Category Figure 5.5. Type of Cannabis Extract Administered to Wild-type Animals 54 Figure 5.6. Number of Wild-type Animal Studies by Type and Number of Animal 54 Subjects Figure 5.7. Number of Animal Models of Human Disease Studies by Type and 55 Number of Animal Subjects Figure 5.8. Type of Human Disease Model Used in Animals 55 Figure 5.9. Type of Cannabis Extract Administered within Animal Models of 55 Human Disease Figure 5.10. Populations studied in human brain studies 57 5 Figure 5.11. Mode of Administration
Load more

Recommended publications
  • Auxly Cannabis Group Inc. Annual Information Form
    AUXLY CANNABIS GROUP INC. ANNUAL INFORMATION FORM FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 May 13, 2020 TABLE OF CONTENTS NOTICE TO READER ............................................................................................................................1 FORWARD-LOOKING STATEMENTS .....................................................................................................1 CORPORATE STRUCTURE ....................................................................................................................4 GENERAL DEVELOPMENT OF THE BUSINESS ........................................................................................5 Three Year History..................................................................................................................................... 5 DESCRIPTION OF THE BUSINESS ........................................................................................................ 14 Overview ................................................................................................................................................. 14 Brand Portfolio ........................................................................................................................................ 14 Current Products ..................................................................................................................................... 15 Product Development ............................................................................................................................
    [Show full text]
  • Management's Discussion and Analysis of Financial Condition and Results of Operations ("Md&A")
    INDIVA LIMITED MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ("MD&A") FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2019 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ("MD&A") The following is a discussion and analysis of the financial condition and results of operations of Indiva Limited ("Indiva" or the "Company") for the three and nine month periods ended September 30, 2019. This MD&A should be read in conjunction with the Company's condensed consolidated interim financial statements and accompanying notes for the three and nine month periods ended September 30, 2019 and 2018 (the "Interim Financial Statements"). All amounts in the MD&A are in Canadian dollars unless indicated otherwise. The Company's accounting policies are in accordance with International Financial Reporting Standards (“IFRS”). The Company’s continuous disclosure documents are available on SEDAR at www.sedar.com. Indiva does not engage in any U.S. marijuana-related activities as defined in CSA Staff Notice 51-352 (Revised) – Issuers with U.S. Marijuana-Related Activities dated February 8, 2018 (the "CSA Notice"). While the Company has partnered with U.S.-based companies, these entities are not engaged in the cultivation, possession or distribution of marijuana. Instead, the Company has partnered with U.S.-based companies which develop and licence intellectual property and copyright branding to the cannabis market, and do not engage in 'plant-touching' activities. The effective date of this MD&A is November 29, 2019. FORWARD-LOOKING STATEMENTS This MD&A includes certain “forward-looking statements” or “forward-looking information” within the meaning of applicable Canadian securities legislation that are based upon current expectations, estimates, projections, assumptions and views of future events of management at the date hereof, and which involve risks and uncertainties associated with our business and the environment in which the business operates.
    [Show full text]
  • Annual Information Form
    CRONOS GROUP INC. ANNUAL INFORMATION FORM For the year ended December 31, 2018 DATED: March 25, 2019 TABLE OF CONTENTS GENERAL MATTERS ............................................................................................................................................... 3 FORWARD LOOKING INFORMATION ............................................................................................................... 3 CORPORATE STRUCTURE .................................................................................................................................... 6 GENERAL DEVELOPMENT OF THE BUSINESS ............................................................................................... 7 DESCRIPTION OF THE BUSINESS ..................................................................................................................... 13 ALTRIA STRATEGIC INVESTMENT ................................................................................................................. 39 RISK FACTORS ....................................................................................................................................................... 43 DIVIDENDS AND DISTRIBUTIONS ..................................................................................................................... 76 CAPITAL STRUCTURE .......................................................................................................................................... 76 MARKET FOR SECURITIES ................................................................................................................................
    [Show full text]
  • Cannabis Legalisation and Regulations in Canada
    CANNABIS LEGALISATION AND REGULATIONS IN CANADA BACKGROUND AND CHALLENGES IVANA OBRADOVIC MEMO NO. 2018-04 SAINT-DENIS, 11 OCTOBER 2018 OVERVIEW Following Uruguay in 2013, Canada is the second country in the world – the first in G7 – that has officially legalised the production, distribution and possession of cannabis for recreational use. Starting October 17, 2018, Canadian adults have been legally able to purchase recreational cannabis produced under licence, to possess up to 30 grams of cannabis and, in most provinces, to grow up to four cannabis plants at home. Canada is the first federal state to propose a decentralised model for the regulation of cannabis. The federal Cannabis Act has introduced an approach focused on public health and youth safety: it creates a strict legal framework to control the production, distribution, sales and possession of cannabis throughout Canada. Federal, provincial and territorial governments share responsibility for overseeing the cannabis regulation system. Conspicuously, provinces and territories have had to figure out their own regulation systems for the distribution Introduction 2 and sale of cannabis and all related safety measures Why legalisation? Context, dynamic and objectives of the reform 2 (for the minimum legal age, quantities and place Context and dynamic of the reform 2 of purchase or use, etc.), whereas municipalities Situational analysis of substance use 2 have the possibility to control use at local level, History of drug reforms 3 even though it remains illegal to transport cannabis A political and electoral argument 3 outside Canadian borders (regardless of quantity). Regain control of the medical cannabis market 5 Eradicating the black market 6 The implementation of this reform involves various Sizeable financial interests 6 jurisdiction levels and diverse regulation systems Legalisation for greater control: the challenge of regulation 7 across the country.
    [Show full text]
  • Classifying Cannabis in the Canadian Statistical System
    Catalogue no. 11-621-M2018105 ISSN 1707-0503 ISBN 978-0-660-24784-7 Analysis in Brief Classifying Cannabis in the Canadian Statistical System by Franklin Assoumou-Ndong Release date: July 24, 2019 How to obtain more information For information about this product or the wide range of services and data available from Statistics Canada, visit our website, www.statcan.gc.ca. You can also contact us by Email at [email protected] Telephone, from Monday to Friday, 8:30 a.m. to 4:30 p.m., at the following numbers: • Statistical Information Service 1-800-263-1136 • National telecommunications device for the hearing impaired 1-800-363-7629 • Fax line 1-514-283-9350 Depository Services Program • Inquiries line 1-800-635-7943 • Fax line 1-800-565-7757 Standards of service to the public Note of appreciation Statistics Canada is committed to serving its clients in a prompt, Canada owes the success of its statistical system to a reliable and courteous manner. To this end, Statistics Canada long-standing partnership between Statistics Canada, the has developed standards of service that its employees observe. citizens of Canada, its businesses, governments and other To obtain a copy of these service standards, please contact institutions. Accurate and timely statistical information Statistics Canada toll-free at 1-800-263-1136. The service could not be produced without their continued co-operation standards are also published on www.statcan.gc.ca under and goodwill. “Contact us” > “Standards of service to the public.” Published by authority of the Minister responsible for Statistics Canada © Her Majesty the Queen in Right of Canada as represented by the Minister of Industry, 2019 All rights reserved.
    [Show full text]
  • Using the 3I+E Framework to Assess Provincial Policy Decisions for the Sale of Cannabis in Ontario, Saskatchewan and Quebec
    Health Policy and Practice Original Research https://doi.org/10.33137/utjph.v2i1.34726 USING THE 3I+E FRAMEWORK TO ASSESS PROVINCIAL POLICY DECISIONS FOR THE SALE OF CANNABIS IN ONTARIO, SASKATCHEWAN AND QUEBEC Ravinder Sandhu1, Guneet Saini1 and Elizabeth Alvarez1 1Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada Corresponding author: Ravinder Sandhu, [email protected] Abstract Objective: This paper examines policy decisions regarding public or private retail models chosen for the recreational use of cannabis in the provinces of Ontario, Saskatchewan and Quebec to demonstrate the application of the 3I+E framework for policy analysis. Methods: The 3I+E framework includes considerations of institutions, interests, ideas and external factors that play a role in adopting a particular policy. A retrospective comparative approach using this framework was conducted. Relevant newspaper articles, press releases, consultation reports and primary policy papers were reviewed. Results: The province of Ontario has a mixed model for the sale of recreational cannabis, while Saskatchewan’s recreational cannabis is fully private and retail in Quebec is through the public sector. Government institutions, particularly the party in power and the number of seats they hold, as well as existing policy legacies for alcohol retail, appeared to strongly influence the policy decisions in all three jurisdictions. Interest groups, including municipal and labor unions and private cannabis com- panies had a limited role in swaying government decisions toward a particular model. Beliefs and values of citizens regarding cannabis retail did not appear to play a significant role. In Ontario particularly, an external factor, namely a major political shift towards a conservative government had a large role in the mixed model chosen in the jurisdiction.
    [Show full text]
  • Management Discussion and Analysis for the Three Months Ended June 30, 2018
    Management Discussion and Analysis For the Three Months Ended June 30, 2018 The following Management’s Discussion and Analysis (“MD&A”) of financial condition and results of operations dated August 29, 2018 relates to unaudited interim condensed consolidated financial statements for the three months ended June 30, 2018 of MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation) (“MPX” or the “Corporation”). This MD&A should be read together with the Corporation’s unaudited interim condensed consolidated financial statements for the three months ended June 30, 2018 together with the related notes as well as the audited consolidated financial statements for the years ended March 31, 2018 and March 31, 2017 together with the related notes. MPX’s consolidated financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”) which requires management to make certain estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and the amount of revenue and expenses incurred during the reporting period. The results of operations for the periods reflected herein are not necessarily indicative of results that may be expected for future periods. Certain statements in this MD&A may contain “forward-looking information”, within the meaning of applicable securities laws, including “safe harbour provisions” of the Securities Act (Ontario) with respect to the Corporation and its subsidiaries. Such statements include, but are not limited to, statements about the growth of the business, production and revenue expectations and the licensing of facilities. These statements are subject to certain risks, assumptions and uncertainties that could cause actual results to differ materially from those included in the forward- looking statements.
    [Show full text]
  • CSE FORM 2A LISTING STATEMENT in Connection with the Listing Of
    CSE FORM 2A LISTING STATEMENT In connection with the listing of MJardin Group, Inc., the entity formed upon the reverse take-over of Sumtra Diversified Inc. by MJAR Holdings Corp. November 13, 2018 MJardin Group, Inc. currently derives substantially all of its current revenues from the cannabis industry in certain states of the United States, which industry is illegal under United States federal law. MJardin Group, Inc. is directly involved (through licensed parties with whom it contracts) in the cannabis industry in the United States where local state laws permit such activities. Currently, its customers are directly, and MJardin Group, Inc. is indirectly through the services provided to such clients, engaged in the manufacture, possession, use, sale or distribution of cannabis in the legal and regulated recreational and/or medicinal cannabis marketplace in the States of Colorado and Nevada. The United States federal government regulates drugs through the Controlled Substances Act (21 U.S.C. § 811), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug. Under United States federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of accepted safety for the use of the drug under medical supervision. The United States Food and Drug Administration has not approved cannabis as a safe and effective drug for any indication. In the United States, cannabis is largely regulated at the state level. State laws regulating cannabis are in direct conflict with the federal Controlled Substances Act, which makes cannabis use and possession federally illegal.
    [Show full text]
  • The Emergence of the Cannabis Act: a Case Study
    The emergence of the Cannabis Act: A case study by Ashley Braun B.A. (Hons.), University of the Fraser Valley, 2017 Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Arts in the School of Criminology Faculty of Arts and Sciences © Ashley Braun 2019 SIMON FRASER UNIVERSITY Spring 2019 Copyright in this work rests with the author. Please ensure that any reproduction or re-use is done in accordance with the relevant national copyright legislation. Approval Name: Ashley Braun Degree: Master of Arts Title: The emergence of the Cannabis Act: A case study Examining Committee: Chair: Bryan Kinney Associate Professor Neil Boyd Senior Supervisor Professor Martin Bouchard Supervisor Professor M-J Milloy External Examiner Assistant Professor Department of Medicine University of British Columbia Date Defended/Approved: April 12, 2019 ii Abstract This case study identifies the key factors that preceded the introduction of the Cannabis Act, using newspaper articles from the Globe and Mail between January 1, 2000 and April 14, 2017. It develops a chronology of cannabis-related events that influenced the social, political, or legal nature of cannabis, and categorizes other stories into five major themes: judicial decisions, medical regulations, commercial industry, international developments, and public opinion. Analysis reveals three key findings that set the stage for legalization, including the government’s failure to create a constitutionally sound cannabis access program, Colorado and Washington’s legal precedent, and a ballooning commercial industry. Law reform benefits, such as product quality, accessibility, and tax revenue are discussed and contrasted with several limitations of the Act, including consumption-related risks, criminal penalties, and ongoing stigma.
    [Show full text]
  • XLY AIF-2020.Pdf
    AUXLY CANNABIS GROUP INC. ANNUAL INFORMATION FORM FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 April 23, 2021 TABLE OF CONTENTS NOTICE TO READER .............................................................................................................................. 1 FORWARD-LOOKING STATEMENTS ...................................................................................................... 1 CORPORATE STRUCTURE ...................................................................................................................... 4 GENERAL DEVELOPMENT OF THE BUSINESS ......................................................................................... 5 Three Year History..................................................................................................................................... 5 DESCRIPTION OF THE BUSINESS ......................................................................................................... 17 Overview ................................................................................................................................................. 17 Brand Portfolio ........................................................................................................................................ 17 Current Products ..................................................................................................................................... 18 Product Development ............................................................................................................................
    [Show full text]
  • Black Market to Blue Chip the Futures of the Cannabis Industry in Canada
    Black Market to Blue Chip The Futures of the Cannabis Industry in Canada By Calla Lee Submitted to OCAD University in partial fulfillment of the requirements for the degree of Master of Design in Strategic Foresight and Innovation Toronto, Ontario, Canada, April, 2018 © Calla Lee, 2018 Declaration I hereby declare that I am the sole author of this MRP. This is a true copy of the MRP, including any required final revisions, as accepted by my examiners. I authorize OCAD University to lend this MRP to other institutions or individu- als for the purpose of scholarly research. I understand that my MRP may be made electronically available to the public. I further authorize OCAD University to reproduce this MRP by photocopying or by other means, in total or in part, at the request of other institutions or individuals for the purpose of scholarly research. Calla Lee ii Abstract The world is changing its mind on cannabis, and we are not in the same world we were in 1923 when Can- ada first made marijuana illegal to smoke. Culture, technology, knowledge, and people have changed. We have a lot more research, seen first-hand how cannabis can help and hurt people, and heard other’s similar and different stories. How do we apply what we’ve learned about strategy, business, and design to turn a prohibition policy into a regulatory framework? Legalization of cannabis in Canada has been delayed to after August, if all things go smoothly and there are no ad- ditional setbacks. Legalization creates a unique opportunity for Canada to become a global leader in innovation, policy, research, and regulation.
    [Show full text]
  • Cannabis Guide for the USA & Canada
    Cannabis Guide for the USA & Canada January 2021 Cannabis Guide for the USA & Canada TABLE OF CONTENTS Message from the Steering Committee .............................................................................. 3 About Meritas ........................................................................................................................... 4 USA United States (Federal) Overview .........5 Minnesota................................................ 71 American Indian and Missouri .................................................... 73 Alaska Native Tribes ................................7 Nevada .................................................... 77 Arizona ..................................................... 12 New Hampshire ..................................... 82 Arkansas .................................................. 17 New Jersey .............................................. 85 California ................................................. 20 New Mexico ............................................ 90 Colorado ................................................. 23 New York ................................................. 94 Delaware ................................................. 27 North Carolina ........................................ 99 Washington, D.C. ................................... 32 Oklahoma.............................................. 103 Florida ...................................................... 34 Oregon ................................................... 109 Georgia ..................................................
    [Show full text]